Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Crystalgenomics Inc. manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions. These actions are distributed across 2 distinct examiners and 2 distinct art units. The busiest examiner is SKOKO III, JOHN JOSEPH, who is responsible for 1 busiest examiner pending office action.
For a practitioner, this distribution across 2 distinct art units suggests that the Biotechnology & Pharmaceuticals technologies being patented may span different sub-specialties. The workload is not concentrated in a single office, as the 2 pending office actions involve 2 distinct examiners. This structure requires managing multiple examiner relationships simultaneously. The diversity in examiners and art units provides a broader base for the company's current prosecution efforts in the biotech sector. Practitioners must coordinate strategies across the 2 distinct art units to maintain consistency in the portfolio. The presence of 2 distinct examiners indicates that the portfolio is subject to multiple independent reviews.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKOKO III, JOHN JOSEPH | 1 | 53.0% | +55.2% |
| RAMOS LEWIS, JOSMALEN MILAGROS | 1 | 55.1% | +28.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17637356 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | SKOKO III, JOHN JOSEPH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17637356 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | SKOKO III, JOHN JOSEPH | — |
| 17283627 | PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR | RAMOS LEWIS, JOSMALEN MILAGROS | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17637356 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | SKOKO III, JOHN JOSEPH | 1643 | §103§112 | Non-Final OA | — | Pending | Feb 22, 2022 |
| 17283627 | PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR | RAMOS LEWIS, JOSMALEN MILAGROS | 1621 | §103Other | Final Rejection | — | Pending | Apr 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCrystalgenomics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
John Joseph Skoko III has the most, with 1 of Crystalgenomics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
